

Making Automation the Standard: An Annex 1 Preview

RAPID MICRO BIOSYSTEMS, 1001 PAWTUCKET BLVD WEST, LOWELL, MA 01854 USA.

SUMMARY

A final version of the European Union (EU) good manufacturing practice (GMP) Annex 1 is expected to be released in late 2021, with potential to advocate automated quality control (QC) technologies as a means of minimizing risk from microbial, particulate, and pyrogen contamination. Developers and makers of sterile pharmaceuticals are keeping a watchful eye on Annex 1 developments for a wide-ranging array of possible compliance challenges, not only in Europe but eventually in the United States.

INTRODUCTION

When a new draft of the European Union (EU) good manufacturing practice (GMP) Annex 1 was published in early 2020, developers and makers of sterile pharmaceuticals were quick to notice that it posed wide-ranging compliance challenges only partially spelled out in the document. Consequently, companies worldwide are looking ahead to the release of a final version later this year, knowing that it is likely to affect not only European standards but also U.S. Food and Drug Administration (FDA) guidelines that could eventually incorporate many of the new principles and provisions.

Annex 1 is primarily concerned with manufacturing, but clearly points to automated quality control (QC) technologies as a means of minimizing risk from microbial, particulate, and pyrogen contamination. Section 2.1 of the Annex, for example, includes this passage identifying key areas for consideration by manufacturers of sterile products:

- i. Facility, equipment and process design should be optimized, qualified, and validated according to the relevant sections of the Good Manufacturing Practices (GMP) guide. The use of appropriate technologies (e.g., Restricted Access Barriers Systems (RABS), isolators, robotic systems, rapid microbial testing and monitoring systems) should be considered to increase the protection of the product from potential extraneous sources of particulate and microbial contamination such as personnel, materials and the surrounding environment, and assist in the rapid detection of potential contaminants in the environment and product.¹

If automated quality control (QC) technologies are endorsed as expected, a critical next step for pharmaceutical firms will be identifying a validated platform capable of accelerating compliance while minimizing risk. The fully validated Growth Direct[®] System is the most notable example, adopted by a majority of Top 20 biopharma manufacturers worldwide with a number of customers already verifying compliance to 21 CFR Part 11 in their own facilities. Consequently, companies hoping to gain a competitive advantage by getting in early on a possible “automation rush” are keeping a close eye on Annex 1 developments.

REDUCING THE RISK OF MANUAL INTERVENTION

Longtime industry observer David Jones, Director of Technical Marketing and Industry Affairs at Rapid Micro Biosystems, expects the Annex to trigger significant changes in the future activities of pharma manufacturers and QC labs.

“At the top level,” Jones notes, “the Annex introduces the need for more risk assessments of processes to scientifically justify what is implemented, and to minimize human intervention in the manufacturing line as the key source of microbial contamination. On an operational level, this emphasis on minimizing human intervention also implies a greater need for automation and robotic handling systems.”

In fact, two sections in Annex 1 specifically suggest use of a rapid, automated microbial method:

9.28 The adoption of suitable rapid or automated monitoring systems should be considered by manufacturers in order to expedite the detection of microbiological contamination issues and to reduce the risk to product. These rapid and automated microbial monitoring methods may be adopted after validation has demonstrated their equivalency or superiority to the established methodology

10.10 Environmental monitoring data and trend data generated for classified areas should be reviewed as part of product batch certification. For products with short shelf life, the environmental data for the time of manufacture may not be available; in these cases, the certification should include a review of the most recent available data. Manufacturers of these products should consider the use of rapid monitoring systems.

As the Annex rightly notes, these methods should only be used after they have been validated to be equivalent or superior to the established method. For this reason, it is important to look at the validation history and regulatory acceptance of rapid automated methods before implementing a new method at a facility.²

CONCLUSION

Annex 1's ten sections are broader in scope than earlier EU guidelines, going beyond medicinal products to a wide range of sterile product types, processes, and technologies.³ Details are relatively sparse, but current industry practices would suggest that any regulatory admonition concerning quality control and risk management issues will ultimately mean big changes at every level of global supply chains.

Due to this broad impact, no single Annex 1 overview or resource can reasonably claim to be definitive. But many supplier companies have issued whitepapers and articles on Annex 1, reviewing potential effects on specific industries from either a manufacturing or microbial testing viewpoint. (See Table 1 below to find examples for further study.)

In the meantime, a beneficial starting point for companies pondering future-ready automation technologies is Rapid Micro Biosystems, the only company currently automating critical compendial microbiology processes with a fully validated technology platform. Already possessing a substantial industry track record deploying its Growth Direct® System, Rapid Micro Biosystems has proven expertise evolving the traditional QC paradigm to meet today's complex regulatory and competitive pressures.

TABLE 1. A sampler of Annex 1 perspectives

| Areas of Interest | Suggested Reading | Topline Summary |
|----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Microbiology impacts | EU GMP Annex 1 - The New Draft and the Implications for Sterile Products Manufacturers | Thorough overview of all Annex sections from a microbiologist's viewpoint |
| Risk analysis, product quality, contamination prevention | EU GMP Annex 1 Manufacture of Sterile Medical Products | Risk analysis implications from a QC consultancy |
| Data integrity, microbial enumeration and ID, quality investigations | Reducing Risk in Your Environmental Monitoring Program | Discusses automated colony counters and the need for viable colonies |
| Cleanroom compliance | FDA and EU GMP Annex 1 Differences in Cleanroom Specifications | Focus on particulates, microbial risk, and rapid microbial monitoring in air sampling |
| Cleanroom disinfection and cleaning | Annex 1: How New Draft Impacts Cleaning and Disinfection in Cleanrooms | Regulatory concerns about hidden effects from residues, as seen by disinfectant manufacturers |
| Isolator manufacturing | Understanding the Impact of Annex 1 on Isolator Operation | Robotics and automation systems figure to be key considerations for aseptic manufacturing in isolators |
| Air sampling | Insight into the New EU GMP Annex 1 | Annex 1 could evolve into the backbone of quality assurance and documentation of contamination control |
| Microbial monitoring, air cleanliness, cGMP | Concerns Around Annex 1 | Strong recommendation for RMM and closer regulatory alignment with industry best practices |

REFERENCES

1. EC. Draft Revision to Annex 1, Manufacture of Sterile Medicinal Products. Brussels, 2020.
https://ec.europa.eu/health/sites/default/files/files/gmp/2020_annex1ps_sterile_medicinal_products_en.pdf
2. Russell, Courtney, Parsaei, Niloufar, and Jones, David L. Validation of the Growth Direct System for Microbial Environmental Monitoring and Define Optimal Incubation Conditions. *European Journal of Parenteral and Pharmaceutical Sciences* 25 (2). June 9, 2020.
<https://www.ejpps.online/validation-of-the-growth-direction>
3. Recasens, Sabine Bessiers and Cser, Tim. How the 2020 Draft EU GMP Annex 1 Changes Will Affect Sterile Pharmaceuticals Manufacturing in North America. *American Pharmaceutical Review*. June 17, 2021.
<https://www.americanpharmaceuticalreview.com/Featured-Articles/576939-QC-Corner-How-the-2020-draft-EU-GMP-Annex-1-changes-will-affect-sterile-pharmaceuticals-manufacturing-in-North-America/>

LEARN MORE

To stay on top of new regulatory developments and automation trends affecting your organization, contact Rapid Micro Biosystems and speak with our experts today.

978.349.3200 • rapidmicrobio.com